Therapeutic Action
Antibacterial, first line antituberculosis antibacterial (sterilising and bactericidal activity), antileprotic antibacterial (bactericidal activity)
PDF page 279
Loading InternPractice…
Drug reference
Antibacterial, first line antituberculosis antibacterial (sterilising and bactericidal activity), antileprotic antibacterial (bactericidal activity)
PDF page 279
Tuberculosis, in combination with other antituberculosis antibacterials Paucibacillary and multibacillary leprosy, in combination with dapsone and clofazimine Brucellosis, in combination with another antibacterial Latent tuberculosis, as monotherapy or in combination with isoniazid
PDF page 279
Do not administer to patients with jaundice, hypersensitivity to rifamycins or history of severe haematological disorders (thrombocytopenia, purpura) during a previous treatment with rifamycins. Avoid or administer with caution to patients with hepatic disorders. May cause: harmless orange-red discoloration of body secretions (urine, tears, saliva, sputum, sweat, etc.); gastrointestinal disturbances (can be taken with a small amount of food to increase gastrointestinal tolerance); headache, drowsiness, hepatotoxicity; influenza-like symptoms; thrombocytopenia, hypersensitivity reactions. If signs of hepatotoxicity (e.g. jaundice) develop, rifampicin should be discontinued until symptoms resolve. Rifampicin reduces the effect of many drugs (antimicrobials, some antiretrovirals, some hormones, antidiabetics, corticosteroids, phenytoin, direct-acting antivirals for chronic hepatitis C, warfarin, etc.): in patients taking nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, use rifabutin in place of rifampicin; in women using contraception, use injectable medroxyprogesterone or an intrauterine device; in the event of concomitant fluconazole administration, administer each drug 12 hours apart (rifampicin in the morning, fluconazole in the evening); for the other drugs, adjust dosage if necessary. Pregnancy: no contra-indication. Risk of maternal and neonatal bleeding disorders when the mother receives rifampicin in late pregnancy: administer phytomenadione (vitamin K) to the mother and the neonate to reduce the risk. Breast-feeding: no contra-indication
PDF page 280
150 mg tablet and 300 mg capsule
PDF page 279
Tuberculosis, latent tuberculosis, as monotherapy or in combination with isoniazid Child under 30 kg: 15 mg/kg once daily, on an empty stomach Child 30 kg and over and adult: 10 mg/kg once daily, on an empty stomach Do not exceed 600 mg daily. Paucibacillary and multibacillary leprosy Child under 10 years: 10 mg/kg once monthly, on an empty stomach Child from 10 to 14 years: 450 mg once monthly, on an empty stomach Child 15 years and over and adult: 600 mg once monthly, on an empty stomach Brucellosis Child: 15 to 20 mg/kg once daily, on an empty stomach (max. 600 mg daily) Adult: 600 to 900 mg once daily, on an empty stomach In patients with hepatic impairment: do not exceed 8 mg/kg/day when treatment is administered daily.
PDF page 279
Tuberculosis: according to protocol Latent tuberculosis as monotherapy: 4 months Latent tuberculosis in combination with isoniazid: 3 months Paucibacillary leprosy: 6 months Multibacillary leprosy: 12 months Brucellosis: 6 weeks
PDF page 280
For patients sensitive to first-line antituberculosis treatment, rifampicin is given as part of a fixed dose combination.
PDF page 280
– – Below 25 °C
PDF page 280
15 mg/kg once daily, on an empty stomach
PDF page 279
10 mg/kg once daily, on an empty stomach
PDF page 279
10 mg/kg once monthly, on an empty stomach
PDF page 279
450 mg once monthly, on an empty stomach
PDF page 279
600 mg once monthly, on an empty stomach
PDF page 279
15 to 20 mg/kg once daily, on an empty stomach (max. 600 mg daily)
PDF page 279